News

Clinical Trials Arena on MSN4d
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
Is Regeneron Stock Undervalued At $500?
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...
Morgan Stanley Trims Regeneron (REGN) Price Target, Maintains Overweight Rating
Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...
Medical Dialogues5d
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...
Pharmabiz6d
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...
pharmaphorum3d
Verona says COPD drug is off to a flying start
Verona Pharma has blockbuster hopes for its recently approved drug for ... phase 3 ENHANCE trials, Ohtuvayre was shown to reduce exacerbation rate and risk over 24 weeks in COPD patients ...
pharmaphorum5d
GSK says Nucala hits the target in new COPD trial
GSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called ... to approve Sanofi and Regeneron's big-selling IL ...